<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2168-622X</issn><issn pub-type="epub">2168-6238</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11966329</article-id><article-id pub-id-type="pmcid-ver">PMC11966329.1</article-id><article-id pub-id-type="pmcaid">11966329</article-id><article-id pub-id-type="pmcaiid">11966329</article-id><article-id pub-id-type="pmid">39841469</article-id><article-id pub-id-type="doi">10.1001/jamapsychiatry.2024.4465</article-id><article-id pub-id-type="publisher-id">yoi240089</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder</article-title><alt-title alt-title-type="headline">Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder</alt-title><alt-title alt-title-type="running-head">Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang-James</surname><given-names initials="Y">Yanli</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="yoi240089aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paliakkara</surname><given-names initials="J">John</given-names></name><degrees>MD</degrees><xref rid="yoi240089aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schaeffer</surname><given-names initials="J">Joshua</given-names></name><degrees>BS</degrees><xref rid="yoi240089aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Strayhorn</surname><given-names initials="J">Joseph</given-names></name><degrees>MD</degrees><xref rid="yoi240089aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Faraone</surname><given-names initials="SV">Stephen V.</given-names></name><degrees>PhD</degrees><xref rid="yoi240089aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="yoi240089aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="yoi240089aff1"><label>1</label>Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York</aff><aff id="yoi240089aff2"><label>2</label>Department of Family Medicine, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York</aff><aff id="yoi240089aff3"><label>3</label>Ross University School of Medicine, Miramar, Florida</aff><aff id="yoi240089aff4"><label>4</label>Clinical Psychology Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York</aff><aff id="yoi240089aff5"><label>5</label>Institute for Human Performance, Department of Neuroscience and Physiology, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> November 12, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> January 22, 2025. doi:<uri content-type="doi">10.1001/jamapsychiatry.2024.4465</uri></p><corresp id="yoi240089cor1"><bold>Corresponding Author:</bold> Yanli Zhang-James, MD, PhD, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, 505 Irving Ave, 3732B NRB, Syracuse, NY 13210 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zhangy@upstate.edu">zhangy@upstate.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Zhang-James had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design</italic>: Zhang-James, Faraone.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data</italic>: All authors.</p><p><italic toggle="yes">Drafting of the manuscript</italic>: Zhang-James, Paliakkara, Schaeffer, Strayhorn.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content</italic>: Zhang-James, Faraone.</p><p><italic toggle="yes">Statistical analysis</italic>: Zhang-James, Paliakkara, Strayhorn, Faraone.</p><p><italic toggle="yes">Administrative, technical, or material support</italic>: Zhang-James, Schaeffer, Faraone.</p><p><italic toggle="yes">Supervision</italic>: Zhang-James, Faraone.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Strayhorn reported holding stock in Amneal Pharmaceuticals, Medtronic, Viatris, Organon, and Bristol Myers Squibb as well as being proprietor of Psychological Skills Press and director of the Organization for Psychoeducational Tutoring outside the submitted work. Dr Faraone reported receiving grants from Otsuka, Corium Pharmaceuticals, Tris Pharmaceuticals, Supernus Pharmaceuticals, Shire/Takeda, Upstate Foundation, European Union&#8217;s Horizon 2020 Research, the National Institutes of Health/National Institute of Mental Health (NIH/NIMH), and Noven; receiving consulting and advisory board fees from Aardvark, Aardwolf, Artificial Intelligence for Mental Health, Atentiv, Axsome, Genomind, Ironshore, Johnson &amp; Johnson/Kenvue, Kanjo, KemPharm/Corium, Noven, Sandoz, Sky Therapeutics, Tris, Arbor, Medice, Ondosis, Rhodes, Supernus, and Vallon; receiving honoraria from Otsuka, Supernus, Tris, and Takeda; holding US Patent US20130217707 A1 (institution and individual); receiving royalties from Elsevier, Guilford Press, and Oxford University Press; holding stock in Aardvark, Aardwolf, Akili, Ironshore, Sky Therapeutics, and Genomind; receiving personal fees for providing writing assistance, medicine, equipment, or administration support to Noven, Vallon, and Supernus; and receiving travel, accommodation and expenses from Ironshore, Supernus, and Otsuka outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> There is no direct funding for this project. Dr Zhang-James&#8217;s research is supported by the European Union&#8217;s Horizon 2020 research and innovation programme under grant agreement 965381.</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI240089-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-01-22T10:00"><day>22</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>82</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">485918</issue-id><fpage>358</fpage><lpage>367</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-04 00:25:23.947"><day>04</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamapsychiatry-e244465.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamapsychiatry-e244465.pdf">jamapsychiatry-e244465.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2024.4465"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="medRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11419232"><article-title>Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder: a retrospective cohort study of electronic health records</article-title><date><day>13</day><month>9</month><year>2024</year></date><elocation-id>2024.09.12.24313553</elocation-id><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2024.09.12.24313553</pub-id><pub-id pub-id-type="pmcid">PMC11419232</pub-id><pub-id pub-id-type="pmid">39314972</pub-id></related-article><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-yoi240089-1"><title>Question</title><p>Are there patterns of comorbidity between intermittent explosive disorder (IED) and other disorders?</p></sec><sec id="ab-yoi240089-2"><title>Findings</title><p>Among 33&#8201;410 individuals identified with a lifetime IED diagnosis (representing only 0.03% of total patients in the electronic health records), 95.7% had at least 1 additional psychiatric diagnosis. Compared with a matched cohort of individuals without an IED diagnosis, significant associations between IED and a wide range of neurological and somatic disorders were found.</p></sec><sec id="ab-yoi240089-3"><title>Meaning</title><p>These findings suggest that more accurate and inclusive diagnosis of IED, along with integrated care approaches addressing the multifaceted health challenges faced by individuals with IED, are needed.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study uses electronic health record data of US individuals to evaluate whether there are patterns of comorbidity between intermittent explosive disorder and other conditions.</p></abstract><abstract><sec id="ab-yoi240089-4"><title>Importance</title><p>Intermittent explosive disorder (IED) is an understudied psychiatric condition marked by impulsive aggression and poorly regulated emotional control, often resulting in interpersonal and societal consequences. Better understanding of comorbidities can improve screening, diagnosis, and treatment.</p></sec><sec id="ab-yoi240089-5"><title>Objective</title><p>To investigate the prevalence of IED and its associations with psychiatric, neurological, and somatic disorders.</p></sec><sec id="ab-yoi240089-6"><title>Design, Setting, and Participants</title><p>In this cohort study, matched groups of patients with and without IED were identified from the TriNetX Research Network (dated January 31, 2024). Electronic medical record data were analyzed. The mean (SD) time from the first to last known visits was 4.8 (5.4) years.</p></sec><sec id="ab-yoi240089-7"><title>Exposure</title><p>Lifetime diagnosis of IED.</p></sec><sec id="ab-yoi240089-8"><title>Main Outcomes and Measures</title><p>Main outcomes were <italic toggle="yes">International Statistical Classification of Diseases, Tenth Revision, Clinical Modification</italic> diagnostic categories and root codes. Cox proportional hazard models were used to estimate and compare probabilities of acquiring other diagnoses. Key measures include the numbers and proportions of patients with these diagnoses and adjusted hazard ratios (HRs) for IED.</p></sec><sec id="ab-yoi240089-9"><title>Results</title><p>Overall, 30&#8201;357 individuals with IED and 30&#8201;357 demographically matched controls were included. In each group, 21&#8201;313 (70%) were male, with a mean (SD) age at the first visit 26 (17) years. Despite only 0.03% of the total patient population having an IED diagnosis, extensive comorbidities with psychiatric, neurological, and somatic conditions were found. A notable 95.7% of individuals with IED (29&#8201;054 individuals) had another psychiatric diagnosis. All psychiatric subcategories and 92% of the psychiatric diagnoses were significantly associated with IED, with HRs ranging from 2.1 (95% CI, 2.0-2.2) for substance use disorder to 76.6 (95% CI, 65.4-89.6) for disorders of adult personality and behavior (excluding IED). Among neurological conditions, neurodegenerative diseases (HR, 5.0; 95% CI, 4.1-6.1) and epilepsy (HR, 4.9; 95% CI, 4.3-5.6) had the highest HRs, followed by movement disorders (HR, 3.1; 95% CI, 2.8-3.5), cerebral palsy (HR, 2.6; 95% CI, 2.2-3.0), and sleep disorders (HR, 2.2; 95% CI, 2.1-2.3). Significant associations with IED were also observed for many somatic diseases, including obesity (HR, 1.6; 95% CI, 1.5-1.7), hyperlipidemia (HR, 1.5; 95% CI, 1.4-1.5), hypertension (HR, 1.6; 95% CI, 1.5-1.7), and gastroesophageal reflux disease (HR, 1.7; 95% CI, 1.7-1.9).</p></sec><sec id="ab-yoi240089-10"><title>Conclusion and Relevance</title><p>These findings highlight the extensive comorbidities between IED and psychiatric, neurological, and somatic disorders, emphasizing the need for integrated diagnostic and treatment approaches addressing both psychological and physical health aspects of IED. Limitations related to reliance on medical records and low diagnostic rates of IED caution the generalizability of these findings, underscoring the need for further validation in prospective studies and more accurate, inclusive diagnosis of IED in patients with mental disorders.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>